Skip to main content
SpringerLink
Log in

Talimogene laherparepvec gets a `no' from NICE

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. a modified form of the herpes simplex virus type 1, designed to kill cancer cells by attacking them directly as well as increasing the ability of the immune system to kill the cancer

Reference

  • NICE. NICE consults on 'no' recommendation for skin cancer drug talimogene laherparepvec. Media Release : 16 Mar 2016. Available from: URL: http://www.nice.org.uk

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Talimogene laherparepvec gets a `no' from NICE. PharmacoEcon Outcomes News 749, 30 (2016). https://doi.org/10.1007/s40274-016-2917-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-016-2917-4

Search

Navigation